MitoImmune is a clinical stage biotech company that focuses on developing drugs for diseases in high unmet needs using mitochondria / ferroptosis based approaches.
Our molecules based on the MIT platform are basically mitochondria-targeted ferroptosis inhibitors which have been demonstrated to recover intracellular homeostasis of iron, calcium, redox, and immune and to preserve antioxidant systems such as GPX4 under pathological conditions where an abnormal increase of mitochondrial reactive oxygen species (ROS) and the accumulation of calcium and iron accumulation occur.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 108, Bongeunsa-Ro, Gangnam-Gu, Seoul, Republic Of Korea, Seoul,korea, Republic Of
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://mitoimmune.com/
- Keywords
- Intervene Immune.
- HQ
- seoul
Mitoimmune Therapeutics Inc. Questions
Mitoimmune Therapeutics Inc.'s website is http://mitoimmune.com/
Mitoimmune Therapeutics Inc.'s LinkedIn profile is https://kr.linkedin.com/company/mitoimmune
Mitoimmune Therapeutics Inc. has
6 employees.
View email and phone details for 6
employees at Mitoimmune Therapeutics Inc..
Mitoimmune Therapeutics Inc.'s industry is
Biotechnology Research
Mitoimmune Therapeutics Inc.'s top competitors are
Pharmaventures,
Scimar,
Curigin Inc.,
Anterogen,
Idience,
Affinity Biopharmaceutical,
J&j Innovative Medicine Korea,
Intervene Immune,
Enzychem Lifesciences,
Inocras Inc..
Mitoimmune Therapeutics Inc.'s categories are Biotechnology Research
Mitoimmune Therapeutics Inc.'s founding year is 2018
